<SEC-DOCUMENT>0001628280-23-007636.txt : 20230313
<SEC-HEADER>0001628280-23-007636.hdr.sgml : 20230313
<ACCEPTANCE-DATETIME>20230313082306
ACCESSION NUMBER:		0001628280-23-007636
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230313
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20230313
DATE AS OF CHANGE:		20230313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		23725804

	BUSINESS ADDRESS:	
		STREET 1:		1460 BROADWAY
		STREET 2:		SUITE 15044
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		1460 BROADWAY
		STREET 2:		SUITE 15044
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ovid-20230313.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:c84cf27f-7f33-479b-8bb1-e5646cc421b6,g:aa1ec203-a3f1-45f6-ae2d-23520462e8e8,d:495b2a3e86e94911ae8bcf5a9bb8ea15--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ovid-20230313</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV80L2ZyYWc6YmU4YTA4YzVhMjYwNGY5MzkxYjFlZDg0NmJkYTM0YzUvdGFibGU6Y2ExMDMzNzZhYjFiNDMwZDg1ZmYyZDZhYjEyY2ZmMGUvdGFibGVyYW5nZTpjYTEwMzM3NmFiMWI0MzBkODVmZjJkNmFiMTJjZmYwZV8yLTEtMS0xLTE0MjM3_b3b2a1a5-fba6-47e3-b902-a333e842b0c0">0001636651</ix:nonNumeric><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV80L2ZyYWc6YmU4YTA4YzVhMjYwNGY5MzkxYjFlZDg0NmJkYTM0YzUvdGFibGU6Y2ExMDMzNzZhYjFiNDMwZDg1ZmYyZDZhYjEyY2ZmMGUvdGFibGVyYW5nZTpjYTEwMzM3NmFiMWI0MzBkODVmZjJkNmFiMTJjZmYwZV8zLTEtMS0xLTE0MjM3_a2f38cd1-7c82-4701-a889-a55962f32063">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ovid-20230313.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-13</xbrli:startDate><xbrli:endDate>2023-03-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i495b2a3e86e94911ae8bcf5a9bb8ea15_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjYw_4f5c8db6-494e-4d0b-bdfa-ad5032ff9a78">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl81NDk3NTU4MTUxNTg_1113ba6e-59dd-4c1b-9efc-37d90738db5a">March&#160;13, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjYx_2bea8635-b902-40d9-bcf4-7b9ab938df39">OVID THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"> (Exact name of Registrant as Specified in Its Charter) </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM18wLTAtMS0xLTE0MjM3_5e4920ba-fbb0-4c88-bbec-fd5cef980622">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM18wLTEtMS0xLTE0MjM3_c9ceb770-acfd-4e90-b423-de68f863ee2f">001-38085</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM18wLTItMS0xLTE0MjM3_093046ff-841c-4c8e-9e0d-287a1bc0db64">46-5270895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(State or Other Jurisdiction</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(IRS Employer</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTE4_27159539-c7d2-42a3-a0d1-b4955a58477d">441 Ninth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTMy_1a0ceaf2-95a1-4914-b39d-1c095c97ece8">14th Floor</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTQz_ff818196-f207-4e57-bde9-f59cc569258f">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTU0_e754b195-328a-447e-8cad-e67942f76905">New York</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTItMS0xLTE0MzA3L3RleHRyZWdpb246MGZmMTlmNDJjZGQ1NGQ2Mjk4YjY2NjFkYmY5M2M0ZWZfNTQ5NzU1ODEzOTAy_3111f613-a535-46da-871e-a9a79233872b">10001</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:40%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjYy_7a564203-0ee5-43bb-a159-26ea873390a2">646</ix:nonNumeric>-<ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjY0_1a60d730-786b-469b-b0b6-5bc7cb29c0b9">661-7661</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N18wLTAtMS0xLTE0MjM3_5bd72d72-ff29-4da2-9bf2-da0f02b7ac6f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N18yLTAtMS0xLTE0MjM3_98cb372f-92b1-48be-b0f5-fed61e078839">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N180LTAtMS0xLTE0MjM3_874cc492-03fc-4f0b-abf1-926bed261b30">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N182LTAtMS0xLTE0MjM3_b7485aef-a810-46ab-8208-69b3d8018a81">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:38.505%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NTFiZWNjNDBiMDIyNDNkNjhjYzdlOWM2NjFlNzdlODQvdGFibGVyYW5nZTo1MWJlY2M0MGIwMjI0M2Q2OGNjN2U5YzY2MWU3N2U4NF8xLTAtMS0xLTE0MjM3_7013330e-a14d-47fe-aa55-ff0d7a638a60">Common Stock, par value $0.001 per share</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NTFiZWNjNDBiMDIyNDNkNjhjYzdlOWM2NjFlNzdlODQvdGFibGVyYW5nZTo1MWJlY2M0MGIwMjI0M2Q2OGNjN2U5YzY2MWU3N2U4NF8xLTItMS0xLTE0MjM3_5c8163c5-3cbd-46a6-b01f-d23b70d2c63d">OVID</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NTFiZWNjNDBiMDIyNDNkNjhjYzdlOWM2NjFlNzdlODQvdGFibGVyYW5nZTo1MWJlY2M0MGIwMjI0M2Q2OGNjN2U5YzY2MWU3N2U4NF8xLTQtMS0xLTE0MjM3_20e27585-b46e-48c6-b2da-2fa1e9e3e636">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8yNzQ4Nzc5MDcwNzU4_5b75ef12-dca1-4364-83b1-ed09d79502b2">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i495b2a3e86e94911ae8bcf5a9bb8ea15_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Ovid Therapeutics Inc. (the &#8220;Company&#8221;) issued a press release announcing Business Update, Fourth Quarter and Full Year 2022 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27.74pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="i495b2a3e86e94911ae8bcf5a9bb8ea15_10"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibit</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="ovid2022exhibit991.htm">Press Release, dated</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">March&#160;13, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i495b2a3e86e94911ae8bcf5a9bb8ea15_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:26.19pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">OVID THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;/s/ Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General Counsel &amp; Corporate Secretary </span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: <ix:nonNumeric contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xMy9mcmFnOmU2YzgzOTc2YjMzYzRhYzBiYmEwODdlNmNhZDZhMGRlL3RleHRyZWdpb246ZTZjODM5NzZiMzNjNGFjMGJiYTA4N2U2Y2FkNmEwZGVfNTQ5NzU1ODE0MTM0_1113ba6e-59dd-4c1b-9efc-37d90738db5a">March&#160;13, 2023</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ovid2022exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="img34400995_0a.jpg" src="img34400995_0a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">OV329 Phase 1 trial is progressing on track</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">An IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company&#8217;s KCC2 activator portfolio</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Takeda's guidance on soticlestat remains unchanged&#59; anticipates regulatory filings in its FY 2024</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Current cash runway expected to fund operations into the first half of 2025 </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NEW YORK, March&#160;13, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ovid Therapeutics Inc. (NASDAQ&#58; OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December&#160;31, 2022.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;Ovid has significant momentum entering 2023. OV329, our next generation GABA aminotransferase inhibitor program, is being actively studied in healthy volunteers. In the first half of 2024, we anticipate data characterizing OV329&#8217;s potential efficacy using a biomarker as well as its initial safety profile. In addition, Takeda is progressing the study of soticlestat in two, pivotal Phase 3 trials of patients with Dravet and Lennox Gastaut syndromes,&#8221; said Jeremy Levin, D.Phil, MB BChir., Chairman and CEO of Ovid Therapeutics. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#34;We continue to refine our development pipeline of differentiated anti-seizure medicines while maintaining fiscal and strategic focus to drive long-term shareholder value,&#8221; remarked Dr. Levin.</font></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_4"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2022 Business Strategy &#38; Update</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">R&#38;D strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Ovid is advancing a differentiated pipeline of programs that use potential first-in-class and best-in-class mechanisms of action to act upon under-addressed biological targets implicated in causing seizures. This pipeline has produced two clinical development programs, soticlestat (which was repurchased by Takeda) and OV329, which are  being studied in Phase 3 and Phase 1 trials, respectively. In addition, the Company continues to advance several research-stage, small molecule anti-seizure programs. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">Financial strategy&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company is directing its capital to programs that it believes represent value-creating opportunities for shareholders and anticipates its cash runway should fund  operations into the first half of 2025. To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year. In addition, Ovid is eligible to receive  non-dilutive capital from Takeda, if and when, soticlestat is successfully approved and marketed. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">Business development strategy&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ovid intends to conduct disciplined business development activities with a focus on clinical stage assets and enabling technologies to complement its portfolio of anti-seizure medicines. Activities focus on in-licensing assets that can increase </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">opportunities to create shareholder value and mitigate risk to shareholders associated with any one program. Updates in 2022 include&#58;</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.11pt;text-decoration:underline">Healx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Healx has been progressing development efforts for gaboxadol (OV101) as part of the agreement that Ovid entered in February 2022, under which Healx secured an exclusive option right to develop and commercialize the compound. Healx stated that it intends to initiate a clinical trial of gaboxadol in combination with another molecule for people living with Fragile X syndrome in 2023. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt;text-decoration:underline">Gensaic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; In August 2022, Ovid entered into a research agreement with Gensaic to harness its novel phage-derived particle (PDP) gene delivery platform for the development of genetic medicines for central nervous system indications. Relative to genetic medicines using viral vectors, Ovid believes PDPs may be optimal for crossing the blood-brain barrier and potentially more cost effective to manufacture.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">Infrastructure &#38; human capital updates&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ovid intends to maintain a concentrated workforce with experts dedicated to antiseizure medicines development. The Company expanded its bench of leaders in Q1 2023, with the addition of Manoj Malhotra, M.D. and Toshiya Nishi, D.V.M. Dr. Malhotra is a recognized board-certified epileptologist who joined Ovid from past leadership roles at the Cleveland Clinic, Eisai, Novartis and Takeda.  Dr. Nishi is the co-inventor of soticlestat and a skilled translational scientist.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline Update &#38; Anticipated Milestones</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">OV329, a potential next generation GABA aminotransferase (GABA-AT) inhibitor, is advancing on track</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">in a Phase 1 trial of healthy volunteers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ovid believes OV329 is more potent than prior GABA-AT inhibitors, and therefore may potentially provide&#58; significant seizure reduction efficacy, an improved safety profile, and preferable (lower) dosing. Ovid anticipates full Phase 1 findings in H1 2024, including biomarker data that may serve as a validated proxy for seizure reduction efficacy.  </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">OV350, one of several compounds in Ovid&#8217;s KCC2 portfolio, has been successfully formulated for potential clinical study as an IV formulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Ovid is evaluating this formulation in several preclinical seizure models and anticipates a possible IND filing in 2024. In addition, development efforts will continue to characterize other compounds in the KCC2 library with a focus on achieving an oral formulation and exploring applications in epilepsies and other brain disorders. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">Takeda is executing two pivotal Phase 3 trials studying soticlestat for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). It previously disclosed that it anticipates regulatory filings in its fiscal year 2024 and confirmed during regularly scheduled communications on March 10, 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Takeda repurchased Ovid's interest in soticlestat in 2021, and Ovid is subsequently eligible to receive regulatory and commercial milestone payments of up to $660 million, as well as royalties up to 20% on global sales, if regulatory approval is received and soticlestat is commercialized. Ovid has no ongoing obligations or costs associated with the development of soticlestat.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.15pt">Genetic medicines for neurodevelopmental conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Ovid is evaluating business development opportunities associated with its non-core nucleic acid programs. </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_7"></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fourth Quarter and Year-End Financial Results 2022 </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash, cash equivalents and marketable securities as of December&#160;31, 2022 totaled $129.0 million.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.15pt">Revenue was $46,280 for the fourth quarter and $1.5 million for the year ended December&#160;31, 2022, as compared to zero and $208.4 million for the same periods in 2021. The annual decrease was due to the receipt of a one-time upfront payment of $196.0 million from Takeda pursuant to the Royalty, License and Termination Agreement associated with soticlestat in 2021. Revenue in 2022 was generated from licensing and other agreements.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.15pt">Research and development expenses were $5.5 million and $24.6 million for the fourth quarter and for the year ended  December&#160;31, 2022, respectively, as compared to $18.1 million and $46.9 million for the same periods in 2021. The annual reduction in expenditures was largely due to cessation of clinical development programs related to gaboxadol and soticlestat, offset by clinical development costs for OV329.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.15pt">General and administrative expenses were $6.7 million and $32.4 million for the fourth quarter and year ended December&#160;31, 2022, as compared to $8.3 million and $37.2 million for the same period in 2021. The annual decrease of $4.8 million was attributed to personnel cost reductions following corporate cost-cutting efforts and headcount reduction conducted in March 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.15pt">Total operating expenses were respectively $12.2 million and $57.1 million in the fourth quarter and year ended December&#160;31, 2022, which were a reduction from $26.4 million and $84.2 million during the same periods last year. The annual decrease was a result of the above mentioned cost cutting and personnel reduction efforts undertaken in 2022. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Ovid reported a net loss of $11.5 million, or basic and diluted net loss per share attributable to common stockholders of $0.16 for the fourth quarter of 2022, as compared to a net loss of $26.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.38, for the same period in 2021. The Company reported net loss of $54.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.77 for the year ended December 31, 2022, compared to a net income of $122.8 million, or basic and diluted net income per share attributable to common stockholders of $1.78 and $1.76, respectively, for the year ended December 31, 2021.</font></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_10"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_13"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Ovid Therapeutics</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid&#8217;s pipeline of small molecule and genetic medicines candidates seek to meaningfully improve the lives of people and families affected by epilepsies and seizure-related disorders. Ovid is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_16"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release includes certain disclosures that contain &#8220;forward-looking statements,&#8221; including, without limitation&#58; statements regarding the Phase 1 study in healthy volunteers for OV329&#59; the potential use of OV329 to treat rare and treatment-resistant forms of epilepsy and seizures&#59; the clinical and regulatory development of OV329, including the anticipated timing of clinical data&#59; the likelihood that data for OV329 will support future development and therapeutic potential&#59; the potential development of OV350 and other KCC2 compounds in Ovid&#8217;s library&#59; the suitability of Ovid&#8217;s library of novel, direct KCC2 transporter activators for a range of formulations and administrations&#59; the timing for filing of Ovid&#8217;s IND applications&#59; the potential benefits of Gensaic's proprietary phage-derived platform&#59; the timing for the completion of Takeda&#8217;s two pivotal Phase 3 trials evaluating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome&#59; and the duration of Ovid&#8217;s expectations regarding its cash runway and the expectation that it will support the advancement of Ovid&#8217;s pipeline. You can identify forward-looking statements because they contain words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expected,&#8221; &#8220;intends,&#8221; &#34;may,&#34; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;seek,&#8221; &#8220;strive&#8221; and &#8220;will,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid&#8217;s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid&#8217;s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid&#8217;s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption &#8220;Risk Factors&#8221; in Ovid&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 8, 2022, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</font></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_19"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.575%"><tr><td style="width:1.0%"></td><td style="width:36.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Three Months Ended December 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Three Months Ended December 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Year Ended December 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Year Ended December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License and other revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,280&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,502,748&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,382,779&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License revenue - related party</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,280&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,502,748&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,382,779&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,545,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,089,614&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,618,399&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,939,583&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,673,710&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,264,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,432,510&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,234,104&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,218,979&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,353,664&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,050,909&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,173,687&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,172,699)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,353,664)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,548,161)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,209,092&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">668,124&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,901&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,379,132&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,690)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,504,576)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,349,763)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,169,029)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,163,402&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(349,714)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,328,818&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,504,576)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,000,049)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,169,029)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,834,584&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.77)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.77)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.76&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,472,598&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,159,651&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,424,819&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,479,403&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,472,598&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,159,651&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,424,819&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,067,992&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_25"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Select Condensed Balance Sheet Data</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,001,411&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:105%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,389,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,680,808&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total assets</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,265,814&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,544,757&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total stockholder's equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,272,564&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,746,436&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">Working capital defined as current assets less current liabilities</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0e64d2f86fb44f4bb393195eeb0a7d26_28"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investors and Media&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ovid Therapeutics Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Meg Alexander</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">917-943-6681</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">malexander&#64;ovidrx.com </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OR</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Argot Partners</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maeve Conneighton</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">212-596-7231</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ovid&#64;argotpartners.com </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ovid-20230313.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c84cf27f-7f33-479b-8bb1-e5646cc421b6,g:aa1ec203-a3f1-45f6-ae2d-23520462e8e8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ovid="http://www.ovidrx.com/20230313" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20230313">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230313_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230313_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ovidrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ovid-20230313_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c84cf27f-7f33-479b-8bb1-e5646cc421b6,g:aa1ec203-a3f1-45f6-ae2d-23520462e8e8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_5354a1ee-97bd-4ddc-a535-c2c2b7eb016e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d4a7d6b0-5656-4700-b80e-51c14dd035b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_cc7cbd2a-f1c4-463b-9125-b83515ef11d4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_932be39e-98c3-4c66-8d08-6100ecd8e8df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bfdf7293-a5ac-453a-b2f9-ffdacae8d7d5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6dad2fd8-4ee0-430d-9389-559c64733fd8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_eeb3849f-df2f-49cf-a1d1-1dbb1b2c500f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0dde67d8-f05e-49a7-9d2a-ce054ff3f70f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5ac013b3-20b8-4124-b164-980a56f7828a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba2e34e7-f624-4851-9c3f-1085e5bdb72a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_431202f9-3695-40d8-b5fb-e2b74f2967e6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_51d22219-df7c-40b9-88c0-d548fc599982_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6620bb66-55a4-4207-8498-cf343da70918_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4734b55a-64af-4e0d-8c27-3aaaec0e2205_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_914122a8-a0c5-445e-8acb-79e5327915cc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_42ebf7aa-1e72-4fc6-8f96-00e86bf8d76f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6e88ae66-0fe5-4965-9b95-e643c2638d8b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e21da78f-02de-43cc-bddf-e7f97fea8f62_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_24da4fd4-7108-4c55-8c32-9c2327a32674_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e7612010-99c6-4d5d-a087-40659c66f6ba_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2055fb85-2f31-4574-9a86-952b339b47c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f68a0783-73ac-48ab-9cd2-834e5d69a9b2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_54478556-243a-4a86-8f8e-cde9597fbea4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ovid-20230313_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c84cf27f-7f33-479b-8bb1-e5646cc421b6,g:aa1ec203-a3f1-45f6-ae2d-23520462e8e8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/Cover" xlink:type="simple" xlink:href="ovid-20230313.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_31a3ad08-f156-48d7-9920-c4fb47a97a36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_DocumentType_31a3ad08-f156-48d7-9920-c4fb47a97a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8fabea82-5f9e-4c67-a931-d4e278941b83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_DocumentPeriodEndDate_8fabea82-5f9e-4c67-a931-d4e278941b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_abdd6196-5a4c-4e76-b489-a19d5e42807e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityRegistrantName_abdd6196-5a4c-4e76-b489-a19d5e42807e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5d62e5c2-242b-46e5-9315-4b1790c0721a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5d62e5c2-242b-46e5-9315-4b1790c0721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ff2cc7b8-c3e5-4eee-b751-c39a87e5f027" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityFileNumber_ff2cc7b8-c3e5-4eee-b751-c39a87e5f027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dc596dba-ea40-4c5e-a7ea-aecad3c9d2d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityTaxIdentificationNumber_dc596dba-ea40-4c5e-a7ea-aecad3c9d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b471ad4d-abb9-4ebd-8b38-f825008e67c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityAddressAddressLine1_b471ad4d-abb9-4ebd-8b38-f825008e67c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_06d363bb-843e-4fc2-8182-d2b55c84f344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityAddressAddressLine2_06d363bb-843e-4fc2-8182-d2b55c84f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_99428e16-7bd6-4f7c-9157-707ce961efb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityAddressCityOrTown_99428e16-7bd6-4f7c-9157-707ce961efb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4caadf53-5a11-494d-91c3-8fe53f9d09e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityAddressStateOrProvince_4caadf53-5a11-494d-91c3-8fe53f9d09e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_00ef81f6-3885-418b-90d2-2ab64810eb1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityAddressPostalZipCode_00ef81f6-3885-418b-90d2-2ab64810eb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7037542a-c64b-436b-b513-71b9fd2fa365" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_CityAreaCode_7037542a-c64b-436b-b513-71b9fd2fa365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_574c5703-ee2f-44d7-b1d4-03abef1f00e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_LocalPhoneNumber_574c5703-ee2f-44d7-b1d4-03abef1f00e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_584efd4a-939c-4e0b-ad0e-09ee154f5ef7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_WrittenCommunications_584efd4a-939c-4e0b-ad0e-09ee154f5ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_22cc70ff-2652-4f30-be83-05618de2eff8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_SolicitingMaterial_22cc70ff-2652-4f30-be83-05618de2eff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_42798949-205b-4391-8810-a4bbc7ddfa00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_PreCommencementTenderOffer_42798949-205b-4391-8810-a4bbc7ddfa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9590a237-1d70-4f01-90a9-864abda5402b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9590a237-1d70-4f01-90a9-864abda5402b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0ac22606-7e5c-4edd-a629-ecb1e08a49d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_Security12bTitle_0ac22606-7e5c-4edd-a629-ecb1e08a49d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_687dec72-0bb5-4d55-9281-5e810521c274" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_TradingSymbol_687dec72-0bb5-4d55-9281-5e810521c274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6e4f6a85-217a-4659-9f49-044828f35334" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_SecurityExchangeName_6e4f6a85-217a-4659-9f49-044828f35334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e4c03dec-4f0d-48db-ab11-d56044cc78d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityEmergingGrowthCompany_e4c03dec-4f0d-48db-ab11-d56044cc78d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e967b8eb-10dc-4248-b8fd-1ad132f9ab07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_EntityCentralIndexKey_e967b8eb-10dc-4248-b8fd-1ad132f9ab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4d118d0c-1b5d-403a-92e5-6f2ccb7d9b48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c3b47556-5b42-4f2a-8f1a-926755f3a956" xlink:to="loc_dei_AmendmentFlag_4d118d0c-1b5d-403a-92e5-6f2ccb7d9b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img34400995_0a.jpg
<TEXT>
begin 644 img34400995_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "G @8# 2(  A$! Q$!_\0
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M:*\#5C%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU2X4Y(Y_Y9J>I[D8]:\V^ ?P=\3_ +9'QJ!O?-_L6&5)M8OE.U+6VSQ$GHS
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MBO+=R,%DD0,I(['!Z5^=_P#P5H^)QN-6\&_#^WF;9;H^LWT6 5+,3' <]=P
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M '>DHGH'[//P!\/?LY_#^W\-Z&GG3,1-?ZA(,27<Y&"[>@[ =A7J-?">I?\
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MOS:_:@^)@^+WQ\\9^)XI%DL[B^:"T=,[6MX@(HVP>FY5!^I-:?[.O[1-_P#
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MRA"%FUO<GE-Y55555&% P!3J**^**/R2_P""J[!?VD-)R<?\4[;]_P#IM/7
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MW]F_]D[QA^T-XHM+6RL9M+\-JV^\UJXB*Q1QC&0F?O.0> .._:O/?BWX:LO
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M444 %%%% !1110 4444 %%%% !1110 4444 )2<=*=24K >7_'SX ^&/VB/
MUSX>\1VX649>RU&)1Y]G-CAT/\UZ$5^5&DWOQ#_X)\_M!I#>,_D*ZFXCB/\
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MQ4/A7]G[XU?'3P?%KGQ'^*VK>$[C5A'<KX?T*)$BM4VC8K<<-P"0.YKD-+^
MEW\#?VS_ ((QW7C36/&/]I1ZNRMJS F#9:-]S'KNY^@K6"]Z?-4N[/36VP'L
M/_!1Q2W[)OB@+P3=6.#Z'[3'@UW?PF_9P\(?#_P7:V5[I-EX@UJY/VS4]7U"
M!9IKR[< R2%F!.">@Z  5PW_  4:_P"34?$O_7W8_P#I5'7TG9_\>D'^XO\
M*N*52<,-!)V5W^@'PW\>_A_:_L^_M<?!SQ]X*L(]*M/%&I#0=8M+=0ENYD94
M#D#^(J[''0&(&O2_V_/'&OZ-\+M$\'>%+E;;Q%XXUF#086\S8XBDSYA5NV3L
M0GT<U!^W)<1?;?@9;;U^TR?$+361,_,5!;)'MDK^=><_\%(_"MUXR^(OP!T>
M.\N-.MM1UR73WOK;[]N\LENJNO\ M ;B/I7;1_?3HRJ/H]?2[0'U!\._V=_
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MTNVN(SN2:&SC5E/J"!Q6\0#U&:PJ2I6M3C;U ^._^"8[ _"/QUM.?^*RO?\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139856927996752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 13,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OVID THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">441 Ninth Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ovid-20230313_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ovid-20230313.xsd" xlink:type="simple"/>
    <context id="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-03-13</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV80L2ZyYWc6YmU4YTA4YzVhMjYwNGY5MzkxYjFlZDg0NmJkYTM0YzUvdGFibGU6Y2ExMDMzNzZhYjFiNDMwZDg1ZmYyZDZhYjEyY2ZmMGUvdGFibGVyYW5nZTpjYTEwMzM3NmFiMWI0MzBkODVmZjJkNmFiMTJjZmYwZV8yLTEtMS0xLTE0MjM3_b3b2a1a5-fba6-47e3-b902-a333e842b0c0">0001636651</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV80L2ZyYWc6YmU4YTA4YzVhMjYwNGY5MzkxYjFlZDg0NmJkYTM0YzUvdGFibGU6Y2ExMDMzNzZhYjFiNDMwZDg1ZmYyZDZhYjEyY2ZmMGUvdGFibGVyYW5nZTpjYTEwMzM3NmFiMWI0MzBkODVmZjJkNmFiMTJjZmYwZV8zLTEtMS0xLTE0MjM3_a2f38cd1-7c82-4701-a889-a55962f32063">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjYw_4f5c8db6-494e-4d0b-bdfa-ad5032ff9a78">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl81NDk3NTU4MTUxNTg_1113ba6e-59dd-4c1b-9efc-37d90738db5a">2023-03-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjYx_2bea8635-b902-40d9-bcf4-7b9ab938df39">OVID THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM18wLTAtMS0xLTE0MjM3_5e4920ba-fbb0-4c88-bbec-fd5cef980622">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM18wLTEtMS0xLTE0MjM3_c9ceb770-acfd-4e90-b423-de68f863ee2f">001-38085</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM18wLTItMS0xLTE0MjM3_093046ff-841c-4c8e-9e0d-287a1bc0db64">46-5270895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTE4_27159539-c7d2-42a3-a0d1-b4955a58477d">441 Ninth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTMy_1a0ceaf2-95a1-4914-b39d-1c095c97ece8">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTQz_ff818196-f207-4e57-bde9-f59cc569258f">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTAtMS0xLTE0MzA1L3RleHRyZWdpb246MTBlMmYwMzUyMjJlNDdlZGE3OThhMDMwOTc0ZjkyZjRfNTQ5NzU1ODE0MTU0_e754b195-328a-447e-8cad-e67942f76905">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6Y2JhZjBiMTQ1NDE5NDliZGIyYzM5M2MzMjNkNTU5ZTMvdGFibGVyYW5nZTpjYmFmMGIxNDU0MTk0OWJkYjJjMzkzYzMyM2Q1NTllM180LTItMS0xLTE0MzA3L3RleHRyZWdpb246MGZmMTlmNDJjZGQ1NGQ2Mjk4YjY2NjFkYmY5M2M0ZWZfNTQ5NzU1ODEzOTAy_3111f613-a535-46da-871e-a9a79233872b">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjYy_7a564203-0ee5-43bb-a159-26ea873390a2">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8xMjY0_1a60d730-786b-469b-b0b6-5bc7cb29c0b9">661-7661</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N18wLTAtMS0xLTE0MjM3_5bd72d72-ff29-4da2-9bf2-da0f02b7ac6f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N18yLTAtMS0xLTE0MjM3_98cb372f-92b1-48be-b0f5-fed61e078839">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N180LTAtMS0xLTE0MjM3_874cc492-03fc-4f0b-abf1-926bed261b30">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NDc1MTgwZGIzODkyNDZlYWFkYzZmNTk4MWNhZTNiNTcvdGFibGVyYW5nZTo0NzUxODBkYjM4OTI0NmVhYWRjNmY1OTgxY2FlM2I1N182LTAtMS0xLTE0MjM3_b7485aef-a810-46ab-8208-69b3d8018a81">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NTFiZWNjNDBiMDIyNDNkNjhjYzdlOWM2NjFlNzdlODQvdGFibGVyYW5nZTo1MWJlY2M0MGIwMjI0M2Q2OGNjN2U5YzY2MWU3N2U4NF8xLTAtMS0xLTE0MjM3_7013330e-a14d-47fe-aa55-ff0d7a638a60">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NTFiZWNjNDBiMDIyNDNkNjhjYzdlOWM2NjFlNzdlODQvdGFibGVyYW5nZTo1MWJlY2M0MGIwMjI0M2Q2OGNjN2U5YzY2MWU3N2U4NF8xLTItMS0xLTE0MjM3_5c8163c5-3cbd-46a6-b01f-d23b70d2c63d">OVID</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGFibGU6NTFiZWNjNDBiMDIyNDNkNjhjYzdlOWM2NjFlNzdlODQvdGFibGVyYW5nZTo1MWJlY2M0MGIwMjI0M2Q2OGNjN2U5YzY2MWU3N2U4NF8xLTQtMS0xLTE0MjM3_20e27585-b46e-48c6-b2da-2fa1e9e3e636">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xL2ZyYWc6NTY1YTRlZjhmMDk4NGI4MWE1NDgxZTAxYzZiNGU5MTYvdGV4dHJlZ2lvbjo1NjVhNGVmOGYwOTg0YjgxYTU0ODFlMDFjNmI0ZTkxNl8yNzQ4Nzc5MDcwNzU4_5b75ef12-dca1-4364-83b1-ed09d79502b2">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5NWIyYTNlODZlOTQ5MTFhZThiY2Y1YTliYjhlYTE1L3NlYzo0OTViMmEzZTg2ZTk0OTExYWU4YmNmNWE5YmI4ZWExNV8xMy9mcmFnOmU2YzgzOTc2YjMzYzRhYzBiYmEwODdlNmNhZDZhMGRlL3RleHRyZWdpb246ZTZjODM5NzZiMzNjNGFjMGJiYTA4N2U2Y2FkNmEwZGVfNTQ5NzU1ODE0MTM0_1113ba6e-59dd-4c1b-9efc-37d90738db5a">2023-03-13</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( .)";58'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ XD)M5I9"_K#N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ XD)M5IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #B
M0FU6'$OG'5P$   =$0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ XD)M5I^@&_"Q @  X@P   T
M         ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #B0FU6EXJ[
M',     3 @  "P              @ %[#P  7W)E;',O+G)E;'-02P$"% ,4
M    " #B0FU6JL0B%C,!   B @  #P              @ %D$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ XD)M5B0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ XD)M5F60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ovid-20230313.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ovid-20230313.htm">ovid-20230313.htm</File>
    <File>ovid-20230313.xsd</File>
    <File>ovid-20230313_lab.xml</File>
    <File>ovid-20230313_pre.xml</File>
    <File>ovid2022exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ovid-20230313.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ovid-20230313.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ovid-20230313_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ovid-20230313_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ovid-20230313.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ovid",
   "nsuri": "http://www.ovidrx.com/20230313",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230313.htm",
      "contextRef": "i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ovidrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230313.htm",
      "contextRef": "i48dd1d87b7754bba8ddac11d0cd44bb2_D20230313-20230313",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-007636-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-007636-xbrl.zip
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M*(D@#">C<V!3)\NW7H4"+:PK7!TP1+D&UEQ.AI1$#R.(130$QN"4)T41'XH
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M<!FK!HMB&BKG"=PK%7A;:R-+S;X"X1%A2NO"TRZ@RV1$1@&/N8*FC-@XY:
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M2P$"% ,4    " #B0FU6 *J]&E86  "OFP  $0              @ $
M;W9I9"TR,#(S,#,Q,RYH=&U02P$"% ,4    " #B0FU6L"ZSPF8"  !H!P
M$0              @ &%%@  ;W9I9"TR,#(S,#,Q,RYX<V102P$"% ,4
M" #B0FU6T7(LMI *   180  %0              @ $:&0  ;W9I9"TR,#(S
M,#,Q,U]L86(N>&UL4$L! A0#%     @ XD)M5@@H_]C/!@  \C(  !4
M         ( !W2,  &]V:60M,C R,S S,3-?<')E+GAM;%!+ 0(4 Q0    (
M .)";5;?_>^6@B   "@I 0 6              "  =\J  !O=FED,C R,F5X
B:&EB:70Y.3$N:'1M4$L%!@     %  4 2 $  )5+      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
